Top
Asthma - Healing Genes
632
post-template-default,single,single-post,postid-632,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Asthma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children (MUPPITS-2)

Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)


Phase 2

DESCRIPTION:

Doctors at several US medical facilities are conducting a large-scale study to learn if an already FDA-approved medication, called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks. While approved for older children, the age range being studied is 6 to 17 years of age. The drug is an antibody that  study will require an injection under the skin every 4 weeks for 56 weeks, and a portion of the participants will receive a placebo injection.

Nucala works by blocking an immune system reaction by eosinophils that contributes to asthma attacks. Learn more about Nucala here.


PATIENT MUST:

  • Be 6 to 17 years of age
  • Lives within appropriate distance from the study center
  • Have a diagnosis of arthritis longer than 1 year prior to enrolling in the study
  • Participant has had ≥2 asthma exacerbations in the prior year
  • Has had varicella or varicella vaccination (chicken pox)
  • Meet criteria regarding the status of their asthma progression and severity

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Visits to the study center every 4 weeks for injection and observation
  3. In-depth follow up at regular 12-week intervals to assess whether the drug is reducing asthma symptoms and severity, for ~ 1 year

LOCATIONS AND CONTACTS:

Several locations are involved in this large study:

Children’s Hospital Colorado in Aurora, Colorado

Contact: Pascuala Pinedo-Estrada  |  720-777-8077 | [email protected]

 

Children’s National Medical Center in Washington, District of Columbia

Contact: Alicia Newcomer  |  202-476-4698  |  [email protected]

 

Ann and Robert Lurie Children’s Hospital of Chicago  in Chicago, Illinois

Contact: Sarah Godley    312-227-6454    [email protected]

 

Boston University School of Medicine in Boston, Massachusetts

Contact: Lisa Gagalis  |  617-414-3263  |  [email protected]

Contact: Edlira Gjerasi  |  (617) 414-3263  |  [email protected]

 

Henry Ford Health System in Detroit, Michigan

Contact: Sherae Hereford  |  313-916-6954  |  [email protected]

Contact: Debbie Emmer  |  313 916-6966  |  [email protected]

 

St. Louis Children’s Hospital in Saint Louis, Missouri

Contact: Beth Tesson  |  314-286-1290  |  [email protected]

 

Columbia University Medical Center New York, New York

Contact: Marcela Pierce  |  212-305-6255  |  [email protected]

 

Cincinnati Children’s Hospital  Cincinnati, Ohio

Contact: Kristi Curtsinger  |  513-803-1651  |  [email protected]

 

University of Texas Southwestern Medical Center Dallas, Texas

Contact: Dolores Santoyo  |  214-648-2620  |  [email protected]

 

SPONSOR INFORMATION:

The National Institute of Allergy and Infectious Diseases (NIAID)

Inner-City Asthma Consortium

GlaxoSmithKline

 

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03292588

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader